Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
43 Results for "
hepatocyte carcinoma
" in MedChemExpress (MCE) Product Catalog:
Products (43)
43 Results for "hepatocyte carcinoma" in MCE Product Catalog:
9
9
9 Publications Verification
Cat. No.: HY-N2334A
CAS No.: 16564-43-5
Synonyms: Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate
2
2 Cited Publications
Target:
Research Areas:
KDM4C-IN-1 is a histone lysine demethylase KDM4C inhibitor with an IC50 of 8 nM. KDM4C-IN-1 inhibits cancer cell proliferation. KDM4C-IN-1 can be used in the research of hepatocellular carcinoma and adenocarcinoma alveolar basal epithelial carcinoma .
1
1 Cited Publications
Cat. No.: HY-W286743
CAS No.: 5746-04-3
Synonyms: CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine
Cat. No.: HY-B0766
CAS No.: 118159-48-1
Synonyms: SY801
Target:
Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species (ROS) Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis
Research Areas:
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .
Cat. No.: HY-D1078
CAS No.: 127770-45-0
Target:
Carboxylesterase (CES) Free Fatty Acid Receptor Reactive Oxygen Species (ROS) Mitochondrial Metabolism Ferroptosis Apoptosis
Research Areas:
GR148672X is an inhibitor of carboxylesterase 1 (CES1) and hepatic microsomal triglyceride hydrolase (TGH). GR148672X blocks the catalytic activity of CES1, impairs the functions of triglyceride and cholesteryl ester lipase, reduces triglyceride mobilization and secretion, and decreases apolipoprotein B-100 secretion in primary rat hepatocytes. Under low-glucose conditions, GR148672X inhibits the survival of colorectal cancer cells by reducing free fatty acid availability, inducing toxic triglyceride accumulation, ROS production, mitochondrial damage, ferroptosis and apoptosis. GR148672X can be used in studies related to colorectal cancer and atherosclerosis .
Cat. No.: HY-N6726
CAS No.: 1422359-85-0
Target:
Cat. No.: HY-P99196
CAS No.: 1174900-84-5
Target:
Research Areas:
Cat. No.: HY-153492A
Purity: 98.82%
Synonyms: AMG 890 sodium; ARC-LPA sodium
Target:
Research Areas:
Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis .
Cat. No.: HY-P2040
CAS No.: 118399-22-7
Cat. No.: HY-N2334AR
CAS No.: 16564-43-5
Synonyms: Chenodeoxycholylglycine sodium salt (Standard); Sodium glycochenodeoxycholate (Standard)
Category:
Category:
Cat. No.: HY-W800805
CAS No.: 2295813-15-7
DOPE-Mal is an N-maleimide-derived phosphatidylethanolamine. DOPE-Mal does not interfere with fatty acyl chains or alter lipid bilayer permeability; it increases lipid bilayer order, reduces fluidity, induces conformational changes in phospholipid polar heads and enhances their hydration. DOPE-Mal can be used as a component to prepare maleimide-displaying liposomes, enabling peptide conjugation via maleimide-thiol coupling. DOPE-Mal can be used to prepare Liposomes for delivering Doxorubicin (HY-15142A) to hepatocytes. DOPE-Mal is applicable to research related to hepatocellular carcinoma and lung cancer .
Cat. No.: HY-W599279
CAS No.: 2761170-84-5
Research Areas:
ABS-752 is an orally active prodrug targeting CRBN-modulating molecular glue with selectivity in protein degradation. ABS-752 preferentially degrades GSPT1 and induces cytotoxicity through this degradation, while it also degrades NEK7, SALL4 and CK1α, with weaker degradation potency against CK1α. As a prodrug, ABS-752 requires metabolic activation to ABT-002 to form the active complex; VAP-1 mediates its conversion to an aldehyde intermediate. ABS-752 induces cell death, reduces cell viability, and exhibits antitumor activity, leading to regression and inhibition of tumor growth. ABS-752 shows no cytotoxicity in primary human hepatocytes. ABS-752 can be used in the research of hepatocellular carcinoma .
Cat. No.: HY-176205
CAS No.: 3024588-48-2
Synonyms: AB801
Target:
Research Areas:
Ligritinib (AB801) is an orally active AXL receptor tyrosine kinase inhibitor, with a IC50 of 1.8 nM, Ki of 0.024 nM, and Kd of 0.093 nM against human targets. It exhibits broad selectivity against the human kinome, including high selectivity for MERTK and TYRO3. Ligritinib blocks the AXL signaling pathway independent of dimerization inducers, and acts as both a tumor growth inhibitor and an AXL inducer. Ligritinib can be used in research related to clear cell renal cell carcinoma, advanced solid tumors, and non-small cell lung cancer .
Cat. No.: HY-175266
Research Areas:
MI1013 is a PROTAC PXR degrader (DC50 = 89 nM, Dmax = 82%). MI1013 degrades PXR in human hepatocellular carcinoma RG cells (HepaRG). MI1013 specifically and safely regulates CYP3A4 promoter activity through PXR degradation. MI1013 affects several key genes involved in sulfate conjugation (e.g., SULT1E1), bile acid synthesis (CYP7A1), gluconeogenesis (PCK1), ketone synthesis (HMGCS20), and hepatocyte proliferation (MKI67). (Pink: PXR ligand 3: HY-175267, Blue: Pomalidomide-propargyl ligand: HY-W410002, Pink + Black: PXR ligand-Linker Conjugate 1: HY-175268) .
Cat. No.: HY-N16513
CAS No.: 105181-07-5
Target:
Cat. No.: HY-177134
CAS No.: 2243235-80-3
Target:
Research Areas:
Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
Research Areas:
BIHC is a TNF blocker with anti-inflammatory activity. BIHC can significantly inhibit the proliferation of hepatocellular carcinoma (HCC) cells and exhibits potent cytotoxicity against the HepG2 cell line, capable of inducing cell apoptosis , while demonstrating relatively low toxicity towards normal hepatocytes. Additionally, BIHC can be used for research on inflammatory bowel disease (IBD) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
